New Three-Drug cocktail targets Hard-to-Treat myeloma
NCT ID NCT05060627
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of three drugs—belantamab mafodotin, carfilzomib, and dexamethasone—in people whose multiple myeloma has returned and is no longer responding to lenalidomide. The trial has two parts: first, finding the safest dose, then testing that dose in up to 60 patients. The goal is to see if the combination can shrink tumors and keep the cancer under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin (a targeted antibody-drug) combined with carfilzomib and dexamethasone
What this could lead to
If successful, this could offer a new treatment option for patients with multiple myeloma that has returned after prior therapy.
What could go wrong
This is an early-phase trial with only 60 patients, so results may not apply broadly. The combination may cause side effects, including eye problems, and may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clínica Universidad de Navarra (CUN)
Pamplona, Spain
-
Complejo Hospitalario Santiago (CHUS)
Santiago de Compostela, Spain
-
Complejo Hospitalario Virgen del Rocío
Seville, Spain
-
H. Gregorio Marañón
Madrid, Spain
-
H. Morales Meseguer
Murcia, Spain
-
H. Son Llatzer
Palma de Mallorca, Spain
-
H. Universitario Marqués de Valdecilla
Santander, Spain
-
H. Universitario de Canarias
Santa Cruz de Tenerife, Spain
-
H.U. La Fe
Valencia, Spain
-
HUCA
Oviedo, Spain
-
Hospital Clinic
Barcelona, Spain
-
Hospital Germans Trias i Pujol (ICO BADALONA)
Badalona, Spain
-
Hospital Universitario 12 de Octubre
Madrid, Spain
-
Hospital Universitario de Salamanca
Salamanca, Spain
-
ICO Duran i Reynals
L'Hospitalet de Llobregat, Spain